As a result, we found alterations in the transcription of four genes (CA2, CCL5, AMIGO1, TLR2) in SMA patients, suggesting those genes contribute to late-onset SMA pathology and could represent new potential therapeutic targets. The gene discussed is CCL5; the disease is proximal spinal muscular atrophy.